Last edition
News about "SKYVaricella"
SK bioscience Files IND for Global Phase 3 Trial of Two-Dose Varicella Vaccine
SK bioscience's Phase 3 clinical trial of SKYVaricella aims to evaluate the immunogenicity and safety of the 2-shot varicella vaccine in roughly 800 children aged 12 months to 12 years, with completion targeted by 2027.
SKYVaricella | 02/09/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members